Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Smith

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The Lancet. Infectious Diseases|August 25, 2014
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trialIman Satti, Joel Meyer, Stephanie A Harris, et al.
Frontiers in Medicine|May 29, 2024
Validating a theory of planned behavior questionnaire for assessing changes in professional behaviors of medical studentsShaista Salman Guraya, Eric Clarke, Asil Sadeq, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Pediatric Blood & Cancer|December 5, 2023
A qualitative study of childhood cancer families' post-treatment needs and the impact of a community-based organization in a rural, socioeconomically disadvantaged, majority Hispanic/Latino regionStephanie M Smith, Anmol Teer, Evelyn Tolamatl Ariceaga, et al.
Cancer Epidemiology|February 5, 2022
The epidemiology of desmoid tumors in DenmarkMarie Anneberg, Helene M L Svane, Jon Fryzek, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
The New England Journal of Medicine|March 8, 2023
Nirogacestat, a γ-Secretase Inhibitor for Desmoid TumorsMrinal Gounder, Ravin Ratan, Thierry Alcindor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2024
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform NeurofibromaChristopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, et al.
CBE Life Sciences Education|March 3, 2010
The genomics education partnership: successful integration of research into laboratory classes at a diverse group of undergraduate institutionsChristopher D Shaffer, Consuelo Alvarez, Cheryl Bailey, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Lancet. Infectious Diseases|August 25, 2014
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trialIman Satti, Joel Meyer, Stephanie A Harris, et al.
Frontiers in Medicine|May 29, 2024
Validating a theory of planned behavior questionnaire for assessing changes in professional behaviors of medical studentsShaista Salman Guraya, Eric Clarke, Asil Sadeq, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Pediatric Blood & Cancer|December 5, 2023
A qualitative study of childhood cancer families' post-treatment needs and the impact of a community-based organization in a rural, socioeconomically disadvantaged, majority Hispanic/Latino regionStephanie M Smith, Anmol Teer, Evelyn Tolamatl Ariceaga, et al.
Cancer Epidemiology|February 5, 2022
The epidemiology of desmoid tumors in DenmarkMarie Anneberg, Helene M L Svane, Jon Fryzek, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
The New England Journal of Medicine|March 8, 2023
Nirogacestat, a γ-Secretase Inhibitor for Desmoid TumorsMrinal Gounder, Ravin Ratan, Thierry Alcindor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2024
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform NeurofibromaChristopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, et al.
CBE Life Sciences Education|March 3, 2010
The genomics education partnership: successful integration of research into laboratory classes at a diverse group of undergraduate institutionsChristopher D Shaffer, Consuelo Alvarez, Cheryl Bailey, et al.
Pageof 8